Adjunctive D-Cycloserine in Major Depressive Disorder
Status:
Active, not recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Transcranial magnetic stimulation (rTMS) is an approved treatment for depression. The purpose
of this study is to test an adjunctive medication, D-cycloserine, in rTMS for depression
using a placebo-controlled design. D-Cycloserine is a partial N-Methyl-D-Aspartate receptor
(NMDAr) agonist, and therefore may enhance the effects of rTMS, however there is data to
support and refute this hypothesis. Using a double-blind design, the investigators will
randomize patients with Major Depressive Disorder to receive either daily low dose
D-cycloserine or placebo in conjunction with rTMS to the left dorsolateral prefrontal cortex.
After 10 treatments (2 weeks), this double-blind period will conclude and all participants
will receive an additional 10 treatments (2 weeks) of rTMS without any adjuncts. The primary
outcome will be improvement in clinician rated depressive symptoms at the conclusion of the
study.